TPG — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Co-investorsEcoR1 CapitalJeito CapitalVida Ventures
Denver, US
James Gregory Barrow(Executive Officer, Director)Jake Bush(Executive Officer, Director, Promoter)Lorrie A. Mahoney(Executive Officer)
Co-investorsAMK Investment OfficeBECO CapitalBessemer Venture PartnersCoatue ManagementCOTU VenturesDST Global+9 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.